Similarly, targeted therapies, particularly VEGF and mTOR inhibitors, disrupt tumor angiogenesis and key oncogenic pathways but often lead to adaptive resistance, necessitating combination strategies (261). This evidence concerns the gene MTOR and neoplasm.